News Â鶹´«Ã½ from Roswell Park Comprehensive Cancer Center Latest news from Roswell Park Comprehensive Cancer Center on News en-us Copyright 2024 News News Â鶹´«Ã½ from Roswell Park Comprehensive Cancer Center 115 31 / /images/newswise-logo-rss.gif Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer /articles/roswell-park-clinical-trial-points-toward-promising-new-therapy-for-most-aggressive-type-of-breast-cancer/?sc=rsin /articles/roswell-park-clinical-trial-points-toward-promising-new-therapy-for-most-aggressive-type-of-breast-cancer/?sc=rsin Mon, 18 Nov 2024 09:50:19 EST A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer. Roswell Park Comprehensive Cancer Center New Computational Method Links One Mammal's Striking Longevity and Resistance to Cancer With 'Dark Genome' /articles/new-computational-method-links-one-mammal-s-striking-longevity-and-resistance-to-cancer-with-dark-genome/?sc=rsin /articles/new-computational-method-links-one-mammal-s-striking-longevity-and-resistance-to-cancer-with-dark-genome/?sc=rsin Tue, 29 Oct 2024 16:00:11 EST The Roswell Park team has developed a new method to measure mutation loads across species, revealing the role of the "dark genome" -- ancient, virus-like genes that affect cellular function. The findings support further exploration of antiviral drugs as potential tools to target the dark genome in controlling cancer. Roswell Park Comprehensive Cancer Center Breakthrough Clinical Trial Reveals Better Treatment for Advanced Classic Hodgkin Lymphoma /articles/breakthrough-clinical-trial-reveals-better-treatment-for-advanced-classic-hodgkin-lymphoma/?sc=rsin /articles/breakthrough-clinical-trial-reveals-better-treatment-for-advanced-classic-hodgkin-lymphoma/?sc=rsin Wed, 16 Oct 2024 20:45:30 EST Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated. Details appear in a study published today in The New England Journal of Medicine. Drs. Kara Kelly of Roswell Park Comprehensive Cancer Center and Sharon Castellino of Children's Healthcare of Atlanta and Emory University School of Medicine/Winship Cancer Institute of Emory University served as pediatric leads of this important trial in children and adults with lymphoma. Roswell Park Comprehensive Cancer Center Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia /articles/study-highlights-promising-new-treatment-option-for-patients-with-treatment-resistant-acute-myeloid-leukemia/?sc=rsin /articles/study-highlights-promising-new-treatment-option-for-patients-with-treatment-resistant-acute-myeloid-leukemia/?sc=rsin Mon, 30 Sep 2024 19:05:32 EST The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML). Roswell Park Comprehensive Cancer Center Disparities Narrowing Among Patients Undergoing Blood Stem Cell Transplant, Roswell Park Study Reveals /articles/disparities-narrowing-among-patients-undergoing-blood-stem-cell-transplant-roswell-park-study-reveals/?sc=rsin /articles/disparities-narrowing-among-patients-undergoing-blood-stem-cell-transplant-roswell-park-study-reveals/?sc=rsin Fri, 20 Sep 2024 10:05:15 EST Open Disparities Narrowing Among Patients Undergoing Blood Stem Cell Transplant, Roswell Park Study Reveals configuration options Historically, some patients with blood cancers have been less likely than others to receive stem cell transplant, also known as bone marrow transplant. Roswell Park Comprehensive Cancer Center Inherited Changes in BRCA Genes Linked to Increased Risk of Multiple Myeloma /articles/inherited-changes-in-brca-genes-linked-to-increased-risk-of-multiple-myeloma/?sc=rsin /articles/inherited-changes-in-brca-genes-linked-to-increased-risk-of-multiple-myeloma/?sc=rsin Tue, 17 Sep 2024 10:05:33 EST A significant number of multiple myeloma patients may have an inherited but previously unrecognized risk of developing the disease, a new study led by Roswell Park Chief of Clinical Genomics Kenan Onel, MD, PhD, reveals. Roswell Park Comprehensive Cancer Center Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer /articles/roswell-park-designed-treatment-regimen-doubles-progression-free-survival-in-metastatic-kidney-cancer/?sc=rsin /articles/roswell-park-designed-treatment-regimen-doubles-progression-free-survival-in-metastatic-kidney-cancer/?sc=rsin Sun, 15 Sep 2024 11:05:00 EST During the European Society for Medical Oncology (ESMO) Congress, Saby George, MD, FACP, of Roswell Park Comprehensive Cancer Center presented findings on a novel two-agent treatment that more than doubled progression-free survival compared with single-agent treatment. Roswell Park Comprehensive Cancer Center Roswell Park Indigenous Cancer Screening/Navigation Success Reaches New Mexico with BMS Foundation Grant /articles/roswell-park-indigenous-cancer-screeningnavigation-success-reaches-new-mexico-with-bms-foundation-grant/?sc=rsin /articles/roswell-park-indigenous-cancer-screeningnavigation-success-reaches-new-mexico-with-bms-foundation-grant/?sc=rsin Mon, 12 Aug 2024 14:05:26 EST A three-year, $689,000 grant from the Bristol Myers Squibb Foundation will enable teams from Roswell Park Comprehensive Cancer Center and the University of New Mexico to collaborate on health navigation services serving the people of the Pueblo Nations. Roswell Park Comprehensive Cancer Center Daily Use of E-Cigarettes Linked to Higher Cigarette Quit Rates, Roswell Park Research Shows /articles/daily-use-of-e-cigarettes-linked-to-higher-cigarette-quit-rates-roswell-park-research-shows/?sc=rsin /articles/daily-use-of-e-cigarettes-linked-to-higher-cigarette-quit-rates-roswell-park-research-shows/?sc=rsin Thu, 01 Aug 2024 12:05:36 EST Adults who used e-cigarettes daily and also smoked combustible cigarettes were more likely to quit smoking than those who smoked but used e-cigarettes less frequently, new research from Roswell Park shows. The findings suggest that daily e-cigarette use may help some people to quit using combustible cigarettes. Roswell Park Comprehensive Cancer Center FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park /articles/fda-expands-orphan-drug-designation-for-survaxm-immunotherapy-developed-at-roswell-park/?sc=rsin /articles/fda-expands-orphan-drug-designation-for-survaxm-immunotherapy-developed-at-roswell-park/?sc=rsin Fri, 21 Jun 2024 13:05:47 EST The FDA has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation applies to SurVaxM as treatment for not just adult glioblastoma but any malignant glioma in children or adults. Roswell Park Comprehensive Cancer Center Roswell Park Insights on Role of Exportin 1 Protein Suggest Strategy for Improving Cancer Immunotherapy /articles/roswell-park-insights-on-role-of-exportin-1-protein-suggest-strategy-for-improving-cancer-immunotherapy/?sc=rsin /articles/roswell-park-insights-on-role-of-exportin-1-protein-suggest-strategy-for-improving-cancer-immunotherapy/?sc=rsin Thu, 20 Jun 2024 19:05:44 EST Research by Hemn Mohammadpour, DVM, PhD, and colleagues at Roswell Park Comprehensive Cancer Center offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy. Their preclinical findings were published today in the journal Cellular & Molecular Immunology. Roswell Park Comprehensive Cancer Center Roswell Park Earns 'Exceptional' Rating from National Cancer Institute With Best-Ever Core Grant /articles/roswell-park-earns-exceptional-rating-from-national-cancer-institute-with-best-ever-core-grant/?sc=rsin /articles/roswell-park-earns-exceptional-rating-from-national-cancer-institute-with-best-ever-core-grant/?sc=rsin Fri, 07 Jun 2024 11:45:56 EST Roswell Park Comprehensive Cancer Center has earned its most highly rated grant from the National Cancer Institute (NCI). The NCI renewed Roswell Park's status as a Comprehensive Cancer Center - a designation held by less than 4% of cancer centers- awarding Roswell Park the highest possible "Exceptional" rating as it renewed a grant Roswell Park has successfully competed for since 1972. Roswell Park Comprehensive Cancer Center Study Reveals Worse Clinical Outcomes in Breast Cancer Patients Who Reported Higher Pain and Stress /articles/study-reveals-worse-clinical-outcomes-in-breast-cancer-patients-who-reported-higher-pain-and-stress/?sc=rsin /articles/study-reveals-worse-clinical-outcomes-in-breast-cancer-patients-who-reported-higher-pain-and-stress/?sc=rsin Thu, 30 May 2024 16:25:45 EST Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS). Roswell Park Comprehensive Cancer Center Study Shows Polygenic Risk Score (PGS) Could Predict Breast Cancer Survival Outcomes /articles/study-shows-polygenic-risk-score-pgs-could-predict-breast-cancer-survival-outcomes/?sc=rsin /articles/study-shows-polygenic-risk-score-pgs-could-predict-breast-cancer-survival-outcomes/?sc=rsin Thu, 30 May 2024 16:00:28 EST Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer. Roswell Park Comprehensive Cancer Center Pathways Study Genotype Data, Alliance A011502 Secondary Analysis Headline Roswell Park ASCO24 Presentations /articles/pathways-study-genotype-data-alliance-a011502-secondary-analysis-headline-roswell-park-asco24-presentations/?sc=rsin /articles/pathways-study-genotype-data-alliance-a011502-secondary-analysis-headline-roswell-park-asco24-presentations/?sc=rsin Fri, 24 May 2024 16:05:13 EST New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week. Roswell Park Comprehensive Cancer Center Roswell Park Research Debunks Perceived Benefits of Overweight/Obesity in Lung Cancer Patients /articles/roswell-park-research-debunks-perceived-benefits-of-overweightobesity-in-lung-cancer-patients/?sc=rsin /articles/roswell-park-research-debunks-perceived-benefits-of-overweightobesity-in-lung-cancer-patients/?sc=rsin Mon, 08 Apr 2024 13:20:29 EST Obesity is associated with a higher risk of developing at least 13 types of cancer -- and worse outcomes after diagnosis. But lung cancer seems to be an exception: Studies have shown that patients with a high body mass index (BMI) experience a lower risk of disease recurrence and longer survival after surgical treatment -- an irregularity called "the obesity paradox." Roswell Park Comprehensive Cancer Center Roswell Park Study First to Show Two-Drug Combination Selectively Targets p53-Mutant Cancers /articles/roswell-park-study-first-to-show-two-drug-combination-selectively-targets-p53-mutant-cancers/?sc=rsin /articles/roswell-park-study-first-to-show-two-drug-combination-selectively-targets-p53-mutant-cancers/?sc=rsin Mon, 26 Feb 2024 11:30:48 EST A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers. Roswell Park Comprehensive Cancer Center Novel Treatment Regimen for FLT3-Mutated Acute Myeloid Leukemia Shows Promise in Roswell Park-Led Study /articles/novel-treatment-regimen-for-flt3-mutated-acute-myeloid-leukemia-shows-promise-in-roswell-park-led-study/?sc=rsin /articles/novel-treatment-regimen-for-flt3-mutated-acute-myeloid-leukemia-shows-promise-in-roswell-park-led-study/?sc=rsin Thu, 08 Feb 2024 15:00:41 EST Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis. Roswell Park Comprehensive Cancer Center Roswell Park Study Defines Mechanisms Underlying Promising Precision Therapy for Pancreatic Cancer /articles/roswell-park-study-defines-mechanisms-underlying-promising-precision-therapy-for-pancreatic-cancer/?sc=rsin /articles/roswell-park-study-defines-mechanisms-underlying-promising-precision-therapy-for-pancreatic-cancer/?sc=rsin Fri, 02 Feb 2024 13:55:44 EST A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer. Roswell Park Comprehensive Cancer Center Simple Blood Protein Tests Predict Which Lymphoma Patients Are Most Likely to Have Poor CAR T Outcomes /articles/simple-blood-protein-tests-predict-which-lymphoma-patients-are-most-likely-to-have-poor-car-t-outcomes/?sc=rsin /articles/simple-blood-protein-tests-predict-which-lymphoma-patients-are-most-likely-to-have-poor-car-t-outcomes/?sc=rsin Fri, 02 Feb 2024 13:40:11 EST As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies. Roswell Park Comprehensive Cancer Center